Drug intelligence / Profile preview

TriMist

Development stage: Preclinical
Lead developer: Dr. Ferrer Biopharma
Modality: Small Molecules
Administration: Intranasal

Overview

TriMist is an intranasal spray in development by Dr. Ferrer BioPharma for the treatment of mild, moderate, and severe allergies and sinusitis. Formulated in partnership with Nanopharm, the drug is a combination of an antihistamine and a corticosteroid. It is designed to reduce allergic and inflammatory nasal symptoms by leveraging the dual mechanism of blocking histamine receptors and exerting anti-inflammatory effects through steroid activity. As of the latest pipeline information, its development status is listed as pending across all clinical stages, indicating it is in the early stages of development.

Brand names: TriMist
Other names: TriMist

Targets

GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on TriMist.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TriMist.

Explore the full profile